Virtual Medical Academy

Communicate Mounjaro value proposition and its use in day-to-day practice for people with type 2 Diabetes and Obesity.

Discuss the latest guidelines and recommendations for obesity management from leading health organizations such as the American Diabetes Association (ADA) and the World Health Organization (WHO).
Describe the appropriate patient selection criteria for new emerging weight management agents
Examine the clinical data that supports the use of GIP/GLP-1 receptor agonists in treatment of type 2 diabetes especially in overweight patients
Illustrate the available strategies of how to manage the side effects of new emerging therapeutic agent during the dose-escalation period
Interpret the latest clinical trial data concerning safety and efficacy of new emerging therapeutic agents indicated for management of weight gain.
Define the unique mechanism of action and dual benefits of GIP/GLP-1 receptor agonists in regulating blood glucose and managing weight, specifically for patients with type 2 diabetes.
Interpret the latest updated guidelines and recommendations concerning the new emerging therapeutic agents that are indicated for regulating blood glucose and managing weight, specifically for patients with type 2 diabetes.